

Merryn Voysey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/633795/publications.pdf>

Version: 2024-02-01

110
papers

18,014
citations

76196

40
h-index

27345

106
g-index

117
all docs

117
docs citations

117
times ranked

27064
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
3	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
4	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174â€™000 participants in 27 randomised trials. <i>Lancet, The</i> , 2015, 385, 1397-1405.	6.3	1,112
5	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	13.9	1,077
6	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
7	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
8	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
9	External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. <i>BMC Medical Research Methodology</i> , 2014, 14, 40.	1.4	483
10	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
11	The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses. <i>JAMA Pediatrics</i> , 2017, 171, 637.	3.3	332
12	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. <i>Lancet, The</i> , 2022, 399, 521-529.	6.3	314
13	Community treatment orders for patients with psychosis (OCTET): a randomised controlled trial. <i>Lancet, The</i> , 2013, 381, 1627-1633.	6.3	298
14	Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. <i>Lancet, The</i> , 2009, 373, 1780-1788.	6.3	270
15	Safety and Immunogenicity of Novel Adenovirus Type 26â€™ and Modified Vaccinia Ankaraâ€™ Vectored Ebola Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1610.	3.8	266
16	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
17	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
18	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV,the</i> , 2021, 8, e474-e485.	2.1	190

#	ARTICLE	IF	CITATIONS
19	Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. <i>New England Journal of Medicine</i> , 2019, 381, 2209-2218.	13.9	147
20	Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. <i>PLoS Medicine</i> , 2017, 14, e1002398.	3.9	142
21	Inhaled Nitric Oxide in Preterm Infants: An Individual-Patient Data Meta-analysis of Randomized Trials. <i>Pediatrics</i> , 2011, 128, 729-739.	1.0	136
22	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV</i> , 2021, 8, e568-e580.	2.1	124
23	Treatment of child anxiety disorders via guided parent-delivered cognitive-behavioural therapy: Randomised controlled trial. <i>British Journal of Psychiatry</i> , 2013, 203, 436-444.	1.7	107
24	Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2-factorial randomised trial. <i>Lancet Psychiatry</i> , 2016, 3, 31-39.	3.7	84
25	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved <i>P. falciparum</i> Parasites Administered by Needle and Syringe. <i>PLoS ONE</i> , 2013, 8, e65960.	1.1	80
26	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
27	Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. <i>Lancet</i> , 2021, 398, 675-684.	6.3	77
28	Non-specific immunological effects of selected routine childhood immunisations: systematic review. <i>BMJ</i> , 2016, 355, i5225.	3.0	69
29	Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004926.	1.3	67
30	Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1075.	3.8	67
31	Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. <i>Clinical Cancer Research</i> , 2012, 18, 3188-3196.	3.2	63
32	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. <i>Journal of Infection</i> , 2015, 71, 43-52.	1.7	61
33	Evaluation of the Clinical and Microbiological Response to <i>Salmonella Paratyphi A</i> Infection in the First Paratyphoid Human Challenge Model. <i>Clinical Infectious Diseases</i> , 2017, 64, 1066-1073.	2.9	60
34	Effects of repeat prenatal corticosteroids given to women at risk of preterm birth: An individual participant data meta-analysis. <i>PLoS Medicine</i> , 2019, 16, e1002771.	3.9	56
35	Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Tybpar TCV). <i>Clinical Infectious Diseases</i> , 2018, 67, 18-24.	2.9	55
36	An Appraisal of the Clinical Features of Pediatric Enteric Fever: Systematic Review and Meta-analysis of the Age-Stratified Disease Occurrence. <i>Clinical Infectious Diseases</i> , 2017, 64, 1604-1611.	2.9	54

#	ARTICLE	IF	CITATIONS
37	Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. <i>BMJ Open</i> , 2015, 5, e008748.	0.8	49
38	Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. <i>The Lancet Global Health</i> , 2021, 9, e1561-e1568.	2.9	48
39	Applying the intention-to-treat principle in practice: Guidance on handling randomisation errors. <i>Clinical Trials</i> , 2015, 12, 418-423.	0.7	47
40	Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. <i>Lancet</i> , The, 2021, 398, 1683-1684.	6.3	47
41	The Early Prevention of Obesity in Children (EPOCH) Collaboration - an Individual Patient Data Prospective Meta-Analysis. <i>BMC Public Health</i> , 2010, 10, 728.	1.2	43
42	Serotype-Specific Correlates of Protection for Pneumococcal Carriage: An Analysis of Immunity in 19 Countries. <i>Clinical Infectious Diseases</i> , 2018, 66, 913-920.	2.9	42
43	Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. <i>The Lancet Global Health</i> , 2021, 9, e1688-e1696.	2.9	42
44	Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells. <i>Vaccine</i> , 2016, 34, 1657-1664.	1.7	38
45	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
46	The Surveillance for Enteric Fever in Asia Project (SEAP), Severe Typhoid Fever Surveillance in Africa (SETA), Surveillance of Enteric Fever in India (SEFI), and Strategic Typhoid Alliance Across Africa and Asia (STRATAA) Population-based Enteric Fever Studies: A Review of Methodological Similarities and Differences. <i>Clinical Infectious Diseases</i> , 2020, 71, S102-S110.	2.9	36
47	Effect of nasal balloon autoinflation in children with otitis media with effusion in primary care: an open randomized controlled trial. <i>Cmaj</i> , 2015, 187, 961-969.	0.9	35
48	Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 760-766.	1.1	34
49	Factors influencing women's attitudes towards antenatal vaccines, group B <i>Streptococcus</i> and clinical trial participation in pregnancy: an online survey. <i>BMJ Open</i> , 2016, 6, e010790.	0.8	34
50	Mixed effects approach to the analysis of the stepped wedge cluster randomised trial – Investigating the confounding effect of time through simulation. <i>PLoS ONE</i> , 2018, 13, e0208876.	1.1	34
51	Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1165-1170.	4.3	33
52	Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer: A Reality Check. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 857-864.	1.2	32
53	Identification of Novel Serodiagnostic Signatures of Typhoid Fever Using a Salmonella Proteome Array. <i>Frontiers in Microbiology</i> , 2017, 8, 1794.	1.5	32
54	Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, S74-S82.	2.9	32

#	ARTICLE	IF	CITATIONS
55	Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study. <i>Oncologist</i> , 2013, 18, 1221-1228.	1.9	30
56	Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 865-873.	1.2	30
57	Treatment of childhood anxiety disorder in the context of maternal anxiety disorder: a randomised controlled trial and economic analysis. <i>Health Technology Assessment</i> , 2015, 19, 1-184.	1.3	30
58	Inhaled Nitric Oxide in preterm infants: a systematic review and individual patient data meta-analysis. <i>BMC Pediatrics</i> , 2010, 10, 15.	0.7	29
59	Effect of Oral Dexamethasone Without Immediate Antibiotics vs Placebo on Acute Sore Throat in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1535.	3.8	29
60	Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. <i>BMJ, The</i> , 2015, 350, h1554-h1554.	3.0	27
61	Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e113-e123.	1.1	27
62	The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies. <i>Clinical Infectious Diseases</i> , 2019, 68, 1265-1273.	2.9	26
63	Psychoeducation and online mood tracking for patients with bipolar disorder: A randomised controlled trial. <i>Journal of Affective Disorders</i> , 2016, 205, 245-251.	2.0	25
64	Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>American Heart Journal</i> , 2012, 163, 508-514.	1.2	24
65	Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 405-414.	4.6	22
66	Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates. <i>Vaccine</i> , 2017, 35, 5850-5857.	1.7	22
67	Self-harm in people with epilepsy: A retrospective cohort study. <i>Epilepsia</i> , 2014, 55, 1355-1365.	2.6	21
68	The Effect of Chronic Cytomegalovirus Infection on Pneumococcal Vaccine Responses. <i>Journal of Infectious Diseases</i> , 2014, 209, 1635-1641.	1.9	19
69	Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age—a phase 3 extension to a randomised controlled trial. <i>Vaccine</i> , 2017, 35, 395-402.	1.7	19
70	A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials. <i>PLoS ONE</i> , 2010, 5, e8580.	1.1	17
71	Repeat prenatal corticosteroid prior to preterm birth: a systematic review and individual participant data meta-analysis for the PRECISE study group (prenatal repeat corticosteroid international IPD) <i>Tj ETQq1 1 0.784314 rgBT /Overloc</i> <i>Reviews</i> . 2012, 1, 12.	2.5	17
72	Prevalence and reporting of recruitment, randomisation and treatment errors in clinical trials: A systematic review. <i>Clinical Trials</i> , 2018, 15, 278-285.	0.7	17

#	ARTICLE	IF	CITATIONS
73	Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, S67-S73.	2.9	17
74	An open randomised study of autoinflation in 4- to 11-year-old school children with otitis media with effusion in primary care. <i>Health Technology Assessment</i> , 2015, 19, 1-150.	1.3	17
75	Understanding paratyphoid infection: study protocol for the development of a human model of <i>Salmonella enterica</i> serovar Paratyphi A challenge in healthy adult volunteers. <i>BMJ Open</i> , 2015, 5, e007481-e007481.	0.8	16
76	Homologous and heterologous re-challenge with <i>Salmonella</i> Typhi and <i>Salmonella</i> Paratyphi A in a randomised controlled human infection model. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008783.	1.3	15
77	The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 787-793.	1.1	14
78	Under-detection of blood culture-positive enteric fever cases: The impact of missing data and methods for adjusting incidence estimates. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007805.	1.3	14
79	Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. <i>Cmaj</i> , 2017, 189, E1276-E1285.	0.9	13
80	Assessment and Translation of the Antibody-in-Lymphocyte Supernatant (ALS) Assay to Improve the Diagnosis of Enteric Fever in Two Controlled Human Infection Models and an Endemic Area of Nepal. <i>Frontiers in Microbiology</i> , 2017, 8, 2031.	1.5	13
81	Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e91413.	1.1	12
82	Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study. <i>Vaccine</i> , 2015, 33, 4579-4585.	1.7	11
83	Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual participant data meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2016, 6, e011680.	0.8	11
84	The predicted persistence and kinetics of antibody decline 9 years after pre-school booster vaccination in UK children. <i>Vaccine</i> , 2016, 34, 4221-4228.	1.7	10
85	Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, e130-e135.	1.1	10
86	The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. <i>Vaccine</i> , 2022, 40, 450-458.	1.7	10
87	Immunological effect of administration of sequential doses of <i>Haemophilus influenzae</i> type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 172-180.	4.6	9
88	Memory B cell response to a PCV-13 booster in 3.5 year old children primed with either PCV-7 or PCV-13. <i>Vaccine</i> , 2017, 35, 2701-2708.	1.7	8
89	Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 156-164.	4.6	8
90	A Bayesian approach for estimating typhoid fever incidence from large-scale facility-based passive surveillance data. <i>Statistics in Medicine</i> , 2021, 40, 5853-5870.	0.8	8

#	ARTICLE	IF	CITATIONS
91	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. <i>EBioMedicine</i> , 2022, 81, 104128.	2.7	8
92	Simulation of Quality-Adjusted Survival in Chronic Diseases. <i>Medical Decision Making</i> , 2011, 31, 559-570.	1.2	7
93	Logistics of Implementing a Large-scale Typhoid Vaccine Trial in Kathmandu, Nepal. <i>Clinical Infectious Diseases</i> , 2019, 68, S138-S145.	2.9	7
94	The impact of administration of conjugate vaccines containing cross reacting material on <i>Haemophilus influenzae</i> type b antibody responses in infants: A systematic review and meta-analysis of randomised controlled trials. <i>Vaccine</i> , 2016, 34, 3986-3992.	1.7	5
95	Melatonin In Acute Mania Investigation (MIAMI). A randomized controlled trial of add-on melatonin in bipolar disorder. <i>Bipolar Disorders</i> , 2021, 23, 176-185.	1.1	5
96	Diagnostic accuracy of Fever-PAIN and Centor criteria for bacterial throat infection in adults with sore throat: a secondary analysis of a randomised controlled trial. <i>BJGP Open</i> , 2021, 5, BJGPO.2021.0122.	0.9	5
97	Oral corticosteroid use for clinical and cost-effective symptom relief of sore throat: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 365.	0.7	4
98	Computing threshold antibody levels of protection in vaccine clinical trials: An assessment of methodological bias. <i>PLoS ONE</i> , 2018, 13, e0202517.	1.1	4
99	The Design and Analysis of Seroefficacy Studies for Typhoid Conjugate Vaccines. <i>Clinical Infectious Diseases</i> , 2019, 68, S183-S190.	2.9	4
100	Assessment of an Antibody-in-Lymphocyte Supernatant Assay for the Etiological Diagnosis of Pneumococcal Pneumonia in Children. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 459.	1.8	3
101	Impact of Vaccination on <i>Haemophilus influenzae</i> Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal. <i>Journal of Infectious Diseases</i> , 2021, 224, S267-S274.	1.9	3
102	Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine. <i>Nature Communications</i> , 2021, 12, 6370.	5.8	3
103	Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, e103-e106.	1.1	2
104	Association of Antibody-Dependent Neutrophil Phagocytosis With Distinct Antibody Glycosylation Profiles Following Typhoid Vaccination. <i>Frontiers in Tropical Diseases</i> , 2021, 2, .	0.5	2
105	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. <i>PLoS ONE</i> , 2016, 11, e0165384.	1.1	2
106	Live attenuated oral vaccine, age and anti-Vi antibody status at baseline significantly affect attack rate in a human <i>Salmonella</i> Typhi challenge model. <i>Journal of Infection</i> , 2015, 71, 689.	1.7	0
107	Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey. <i>Vaccine</i> , 2015, 33, 7203-7210.	1.7	0
108	Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. <i>Vaccine</i> , 2016, 34, 6350-6357.	1.7	0

#	ARTICLE	IF	CITATIONS
109	Use of weighted multivariate estimates in trials of multi-serotype vaccines to simplify interpretation of treatment differences. PLoS ONE, 2018, 13, e0196200.	1.1	0
110	Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers. Pediatric Infectious Disease Journal, 2021, 40, 937-943.	1.1	0